ClinicalTrials.gg
CompletedNCT00579982Updated Dec 16, 2016Results posted

An Open-Label Trial Measuring Satisfaction And Convenience Of Two Formulations Of Lamotrigine In Subjects With A Mood Disorder

A Phase 3 interventional study of Lamotrigine in Mood Disorders, sponsored by GlaxoSmithKline. Completed at 18 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-12-16.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
97
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 269 studies in Mood Disorders with a site in United States — 37 open to participants now, 44 under way, 2 of them phase 3. Mood Disorders · United States.

Enrollment
94th of 210
97 · median 81
Started
2008
with 11 others
Phase 3
16 of 269
2 open now
Registered
69th of 269
by date

Among the 269 studies in Mood Disorders with a site in United States, this one is the 94th largest by enrollment of the 210 interventional ones that give a count, is one of 12 that started in 2008, is one of 16 in phase 3, and was the 69th registered.

Mood Disorders

562 studies on the registry are indexed under Mood Disorders; 106 are open to participants now.

Browse Mood Disorders studies →

Open to participants now

37 of the 269 studies in Mood Disorders with a site in United States are open now. Recruiting first, the newest first:

32 more — sign in →

All 37 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 78 Mood Disorders studies recruiting now, 21 (27%) set no upper age limit and 46 (59%) stop at 75 or younger; 21 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 269 studies in Mood Disorders with a site in United States, or all of them as a file.
02

Study summary

To determine the convenience and satisfaction of new orally disintegrating tablet formulation (ODT) of lamictal in subjects with a mood disorder. This was a multicenter, open-label study in participants with a mood disorder, who reported difficulty or discomfort in swallowing the currently marketed IR compressed tablet formulation of lamotrigine and who had a person (such as a spouse, partner, companion, aid, nurse, caregiver, etc) willing to complete a Companion/Caregiver Question. Subjects were switched from the currently marketed lamotrigine IR formulation to a matching dose of lamotrigine IR orally disintegrating tablet (ODT) for 3 weeks to determine convenience and satisfaction.

03

Conditions studied

  • Mood Disorders

Browse trials for

Keywords

  • Mood disorder
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject must have a documented diagnosis of a mood disorder as defined by (DSM)-IV (296.00-296.90).
  • Subject must have a person (such as a spouse, partner, companion, aid, nurse, caregiver, etc) willing to complete a Companion/Caregiver Preference Question either in person or via the telephone. This individual must read, write, and comprehend English at a level sufficient to complete study-related assessments.
  • Subject must have been taking a stable dose of currently marketed compressed tablet formulation of lamotrigine IR for at least 4 weeks prior to Baseline (Day 1) of the study and must be adherent to the prescribed dosing regimen. The current dose must not exceed 600 mg/day.
  • Subject's current lamotrigine IR dose, frequency and number of tablets per administration must remain consistent between the IR and ODT regimens. However, the subject's current lamotrigine IR dose may be such that the subject would receive no more than one additional ODT per administration in order to equal their IR dose.
  • Subject must currently report a difficulty or discomfort swallowing lamotrigine IR compressed tablets, the nature of which is or will be documented. NOTE: A diagnosis of dysphagia is not required.
  • Subject must have the ability to comprehend the consent form and provide .
  • Subject must read, write, and comprehend English at a level sufficient to complete study-related assessments.
  • Subject is a male or female at least 18 years of age.
  • If female, the subject is eligible to enter and participate in this study if she is not lactating and is of:

    1. non- (i.e., physiologically incapable of becoming pregnant, including any female who is pre-menarchal or [defined as one year without menses]); is surgically sterile [via hysterectomy and/or removal of the ovaries] or,
    2. child-bearing potential, has a negative pregnancy test at both Screening and/or Baseline (prior to Product administration), and agrees to one of the following requirements:
  • has a male sexual partner who is surgically sterilized (vasectomy with documentation of azoospermia) prior to Screening or,
  • sexual partner(s) is/are exclusively female or,
  • double barrier method: condom or occlusive cap (diaphragm or cervical/vault caps) plus spermicidal agent (foam/gel/film/cream/suppository). The subject must be using this method for at least 1 week following the discontinuation of Investigational Product or,
  • any intrauterine device (IUD) with published data showing that the highest expected failure rate is less than 1% per year. Acceptable IUDs, for the purposes of this study, include TCu-380A (Paragard), TCU-380 Slimline (Gyne T Slimline), MULTILOAD-250 (MLCu-250) and 375, Levonorgesterol LNG-20 Intrauterine System (Mirena/Levonova), and Flexigard 330/CuFix PP330 (Gynefix).The subject must have had the device inserted at least 2 weeks prior to Screening, throughout the study, and 2 weeks following the discontinuation of Investigational Product.

Exclusion criteria

Exclusion Criteria:

  • Subject has:
  • a current (or within six months prior to Screening) diagnosis of anorexia nervosa or bulimia.
  • a diagnosis of a mood disorder due to a general medical condition, or substance abuse per (293.83).
  • a diagnosis of schizophrenia or other psychotic disorders.
  • Subject who meets current criteria of an acute mood disorder and has a CGI-S of ≥4 at Screening.
  • Subject who crushes lamotrigine IR compressed tablet prior to taking or receiving medication orally.
  • Subject who, in the investigator's judgment, poses a homicidal or serious suicidal risk; has made a suicide attempt within the six months preceding Screening; or has ever been homicidal.
  • Subject who has a score of 1 or greater on Suicidality item (Item 9) of the BDI-II at Screening and/or Baseline.
  • Subject has ever experienced a rash related to prior lamotrigine treatment, or for whom treatment was discontinued for safety reasons.
  • Subject has a history of severe hepato-biliary disease within the past 3 years.
  • Subject has any medical condition that, in the investigator's judgment, is considered to be clinically significant and could potentially affect subject safety or study outcome.
  • Subject has a positive urine test at Screening for illicit drug use and/or a history of alcohol or substance abuse or dependence within the past 12 months.
  • Subject is currently participating in another clinical study in which the subject is or will be exposed to an or non-investigational drug or device, or has done so within the preceding month for studies unrelated to the current illness, or six months for studies related to the current illness.
  • Female subject is pregnant, lactating, or does not agree to use method(s) specified in the protocol to avoid pregnancy during the study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
97 participants (actual)

Study arms

  • Experimental
    Arm 1

    Lamictal orally disintegrating tablet (ODT)

    Drug: Lamotrigine

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in the Convenience Subscale Score (CSS) Derived From the Treatment Satisfaction Questionnaire for Medication (TSQM v 1.4) Using Items 9 (Ease of Use), 10 (Ease of Planning to Use), and 11 (Convenience) at Week 3.

    The CSS is the sum of items 9 (values: 1=Extremely difficult - 7=Extremely easy), 10 (same set of values as for 9), and 11 (1=Extremely inconvenient - 7=Extremely convenient). The sum has 3 subtracted from it, is divided by 18, and then multiplied by 100; the range is 0-100. Change from baseline=end of study CSS minus baseline score.

    Time frame: Baseline, End of Study (Week 3) or Early Withdrawal

Secondary outcomes

  1. Mean Change From Baseline in the Global Satisfaction Subscale Score, From the TSQM Using Items 12 (Confidence in Medicine), 13 (Certainty That Good Things About Medication Outweigh Bad Things), and 14 (Satisfaction With Medication) at Week 3

    The Global Satisfaction Subscale Score is the sum of item 12 (values: 1=Not at all confident - 5=Extremely confident), item 13 (values: 1=Not at all certain - 5=Extremely certain), and item 14 (Extremely dissatisfied - 7=Extremely satisfied). The sum has 3 subtracted from it, is divided by 14, and then multiplied by 100; thus, the range is 0-100.

    Time frame: Baseline, End of Study (Week 3) or Early Withdrawal

  2. Mean Change From Baseline in Clinical Global Impression of Illness-Severity at Week 3

    Clinician assessment evaluating how mentally ill the patient is at time of evaluation. The questionnaire is based on a 7-point scale (from1 = Normal to 7 = Among the most extremely ill patients).

    Time frame: Baseline, End of Study (Week 3) or at Early Withdrawal

  3. Mean Change From Baseline in the Beck Depression Inventory (BDI-II) Score at Week 3

    Participant-reported questionnaire consisting of 21 items on a 4 point scale (0 to 3, with 3 indicating most severely ill), with the score being the sum of the items. The change from baseline is the end of study score minus the baseline score; larger values indicate more depression with the ODT formulation relative to the IR formulation.

    Time frame: Baseline, End of Study (Week 3 weeks) or at Early Withdrawal

  4. Number of Participants Answering the Question "Did the Tablets Dissolve Instantly (Yes or no)?" at Week 3

    The Organoleptic Questionnaire (9 items) was used to assess the participants' satisfaction with the physical characteristics of the ODT formulation e.g. rate of dissolution, flavor. Question number 1 on organoleptic questionnaire: Did the tablets dissolve instantly (yes or no)?

    Time frame: End of Study (Week 3) or Early Withdrawal

  5. Number of Participants Answering the Question "How Satisfied or Dissatisfied Were You With the Time it Took the Tablet to Dissolve" at Week 3

    Question number 2 on organoleptic questionnaire: How satisfied or dissatisfied were you with the time it took the tablet to dissolve? \[from a rating of 1 (Extremely dissatisfied) to 5 (Extremely satisfied)\]

    Time frame: Baseline, End of Study (Week 3) or Early Withdrawal

  6. Number of Participants Answering the Question "How Did the Dissolved Tablet Feel in Your Mouth?" at Week 3

    Question number 3 on organoleptic questionnaire: How did the dissolved tablet feel in your mouth? \[from a rating of 1 (Extremely gritty) to 5 (Extremely smooth)\]

    Time frame: End of Study (Week 3) or Early Withdrawal

  7. Number of Participants Answering the Question "How Satisfied Were You With the Flavor of the Tablet?" at Week 3

    Question number 4 on organoleptic questionnaire: How satisfied were you with the flavor of the tablet? \[from a rating of 1 (Extremely dissatisfied) to 5 (Extremely satisfied)\]

    Time frame: End of Study (Week 3) or Early Withdrawal

  8. Number of Participants Answering the Question "How Would You Rate the Strength of the Flavor of the Tablet"? at Week 3

    Organoleptic Questionnaire, question 5: How would you rate the strength of the flavor of the tablet? \[from 1 a rating of (Extremely bothersome) to 5 (Extremely pleasant)\]

    Time frame: End of Study (Week 3) or Early Withdrawal

  9. Number of Participants Answering the Question "How Would You Rate the Aftertaste of the Tablet"? at Week 3.

    Organoleptic Questionnaire, question 6: How would you rate the aftertaste of the tablet (the taste remaining in your mouth after swallowing the tablet)? \[from a rating of 1 (Extremely bothersome) to 6 (Did NOT experience an aftertaste)\]

    Time frame: End of Study (Week 3) or Early Withdrawal

  10. Number of Participants Answering the Question "How Satisfied Were You With the Aftertaste of the Tablet"? at Week 3

    Organoleptic Questionnaire, question 7: How satisfied were you with the aftertaste of the tablet (the taste remaining in your mouth after swallowing the tablet)? \[from a rating of 1 (Extremely dissatisfied) to 6 (I did NOT experience an aftertaste)\]

    Time frame: Baseline, End of Study (Week 3) or Early Withdrawal

  11. Number of Participants Answering the Question "Compared to Standard Tablets That Need to be Swallowed With Liquid, How Convenient or Inconvenient Did You Find This Orally Disintegrating Tablet"? at Week 3

    Organoleptic Questionnaire, question 8: Compared to standard tablets that need to be swallowed with liquid, how convenient or inconvenient did you find this orally disintegrating tablet? (from a rating of 1 \[Extremely inconvenient\] to 5 \[Extremely convenient\])

    Time frame: End of Study (Week 3) or at Early Withdrawal

  12. Number of Participants Answering the Question "Compared to Standard Tablets That Need to be Swallowed With Liquid, How Easy or Difficult is it to Use This Orally Disintegrating Tablet?" at Week 3

    Organoleptic Questionnaire, question 9: Compared to standard tablets that need to be swallowed with liquid, how easy or difficult is it to use this orally disintegrating tablet? \[from a rating of 1 (Extremely difficult) to 5 (Extremely easy)\]

    Time frame: End of Study (Week 3) or at Early Withdrawal

  13. Number of Participants Indicating a Preference for ODT or the Standard IR Tablet at Week 3

    Participant indicated whether preference was for ODT or the standard IR tablet

    Time frame: End of Study (Week 3) or at Early Withdrawal

  14. Number of Companions/Caregivers Indicating Whether ODT or Standard IR Tablet is More Convenient at Week 3

    Companion/Caregiver indicates whether ODT is more convenient or standard IR tablet is more convenient

    Time frame: End of Study (Week 3) or at Early Withdrawal

  15. Number of Participants Indicating at Week 3 (by Answering Yes/no) That They Would be More Likely to Take the ODT Formulation

    Tablet Routine Questionnaire (Adherence): Adherence to the treatment was evaluated by asking if the participant would be more likely to take the ODT formulation (yes/no)

    Time frame: End of Study (Week 3) or at Early Withdrawal

07

Results

Posted Aug 3, 2009

Participant flow

Participant flow — Overall Study
MilestoneLamotrigine
Started97
Completed89
Not completed8
Withdrew: Adverse event4
Withdrew: Protocol violation4

Outcome measures

PrimaryMean Change From Baseline in the Convenience Subscale Score (CSS) Derived From the Treatment Satisfaction Questionnaire for Medication (TSQM v 1.4) Using Items 9 (Ease of Use), 10 (Ease of Planning to Use), and 11 (Convenience) at Week 3.

The CSS is the sum of items 9 (values: 1=Extremely difficult - 7=Extremely easy), 10 (same set of values as for 9), and 11 (1=Extremely inconvenient - 7=Extremely convenient). The sum has 3 subtracted from it, is divided by 18, and then multiplied by 100; the range is 0-100. Change from baseline=end of study CSS minus baseline score.

Time frame:
Baseline, End of Study (Week 3) or Early Withdrawal
Reported as:
Mean · Points on a subscale
Mean Change From Baseline in the Convenience Subscale Score (CSS) Derived From the Treatment Satisfaction Questionnaire for Medication (TSQM v 1.4) Using Items 9 (Ease of Use), 10 (Ease of Planning to Use), and 11 (Convenience) at Week 3.
Points on a subscaleLamotrigine
Mean Change From Baseline in the Convenience Subscale Score (CSS) Derived From the Treatment Satisfaction Questionnaire for Medication (TSQM v 1.4) Using Items 9 (Ease of Use), 10 (Ease of Planning to Use), and 11 (Convenience) at Week 3.23.3 ± 22.5
Statistical analysis
  • Lamotrigine · t-test, 2 sided · p = <0.001 (Paired t-test)
SecondaryMean Change From Baseline in the Global Satisfaction Subscale Score, From the TSQM Using Items 12 (Confidence in Medicine), 13 (Certainty That Good Things About Medication Outweigh Bad Things), and 14 (Satisfaction With Medication) at Week 3

The Global Satisfaction Subscale Score is the sum of item 12 (values: 1=Not at all confident - 5=Extremely confident), item 13 (values: 1=Not at all certain - 5=Extremely certain), and item 14 (Extremely dissatisfied - 7=Extremely satisfied). The sum has 3 subtracted from it, is divided by 14, and then multiplied by 100; thus, the range is 0-100.

Time frame:
Baseline, End of Study (Week 3) or Early Withdrawal
Reported as:
Mean · Points on a subscale
Mean Change From Baseline in the Global Satisfaction Subscale Score, From the TSQM Using Items 12 (Confidence in Medicine), 13 (Certainty That Good Things About Medication Outweigh Bad Things), and 14 (Satisfaction With Medication) at Week 3
Points on a subscaleLamotrigine
Mean Change From Baseline in the Global Satisfaction Subscale Score, From the TSQM Using Items 12 (Confidence in Medicine), 13 (Certainty That Good Things About Medication Outweigh Bad Things), and 14 (Satisfaction With Medication) at Week 3-0.3 ± 29.34
SecondaryMean Change From Baseline in Clinical Global Impression of Illness-Severity at Week 3

Clinician assessment evaluating how mentally ill the patient is at time of evaluation. The questionnaire is based on a 7-point scale (from1 = Normal to 7 = Among the most extremely ill patients).

Time frame:
Baseline, End of Study (Week 3) or at Early Withdrawal
Reported as:
Mean · Points on a scale
Mean Change From Baseline in Clinical Global Impression of Illness-Severity at Week 3
Points on a scaleLamotrigine
Mean Change From Baseline in Clinical Global Impression of Illness-Severity at Week 30.0 ± 0.81
SecondaryMean Change From Baseline in the Beck Depression Inventory (BDI-II) Score at Week 3

Participant-reported questionnaire consisting of 21 items on a 4 point scale (0 to 3, with 3 indicating most severely ill), with the score being the sum of the items. The change from baseline is the end of study score minus the baseline score; larger values indicate more depression with the ODT formulation relative to the IR formulation.

Time frame:
Baseline, End of Study (Week 3 weeks) or at Early Withdrawal
Reported as:
Mean · Points on a scale
Mean Change From Baseline in the Beck Depression Inventory (BDI-II) Score at Week 3
Points on a scaleLamotrigine
Mean Change From Baseline in the Beck Depression Inventory (BDI-II) Score at Week 3-1.7 ± 9.52
SecondaryNumber of Participants Answering the Question "Did the Tablets Dissolve Instantly (Yes or no)?" at Week 3

The Organoleptic Questionnaire (9 items) was used to assess the participants' satisfaction with the physical characteristics of the ODT formulation e.g. rate of dissolution, flavor. Question number 1 on organoleptic questionnaire: Did the tablets dissolve instantly (yes or no)?

Time frame:
End of Study (Week 3) or Early Withdrawal
Reported as:
Number · Number of participants
Number of Participants Answering the Question "Did the Tablets Dissolve Instantly (Yes or no)?" at Week 3
Number of participantsLamotrigine
Yes60
No37
SecondaryNumber of Participants Answering the Question "How Satisfied or Dissatisfied Were You With the Time it Took the Tablet to Dissolve" at Week 3

Question number 2 on organoleptic questionnaire: How satisfied or dissatisfied were you with the time it took the tablet to dissolve? \[from a rating of 1 (Extremely dissatisfied) to 5 (Extremely satisfied)\]

Time frame:
Baseline, End of Study (Week 3) or Early Withdrawal
Reported as:
Number · Number of participants
Number of Participants Answering the Question "How Satisfied or Dissatisfied Were You With the Time it Took the Tablet to Dissolve" at Week 3
Number of participantsLamotrigine
Extremely dissatisfied3
Very dissatisfied10
Satisfied37
Very satisfied18
Extremely satisfied29
SecondaryNumber of Participants Answering the Question "How Did the Dissolved Tablet Feel in Your Mouth?" at Week 3

Question number 3 on organoleptic questionnaire: How did the dissolved tablet feel in your mouth? \[from a rating of 1 (Extremely gritty) to 5 (Extremely smooth)\]

Time frame:
End of Study (Week 3) or Early Withdrawal
Reported as:
Number · Number of participants
Number of Participants Answering the Question "How Did the Dissolved Tablet Feel in Your Mouth?" at Week 3
Number of participantsLamotrigine
Extremely gritty0
Very gritty19
Smooth45
Very smooth19
Extremely smooth14
SecondaryNumber of Participants Answering the Question "How Satisfied Were You With the Flavor of the Tablet?" at Week 3

Question number 4 on organoleptic questionnaire: How satisfied were you with the flavor of the tablet? \[from a rating of 1 (Extremely dissatisfied) to 5 (Extremely satisfied)\]

Time frame:
End of Study (Week 3) or Early Withdrawal
Reported as:
Number · Number of participants
Number of Participants Answering the Question "How Satisfied Were You With the Flavor of the Tablet?" at Week 3
Number of participantsLamotrigine
Extremely dissatisfied5
Very dissatisfied10
Satisfied26
Very satisfied23
Extremely satisfied33
SecondaryNumber of Participants Answering the Question "How Would You Rate the Strength of the Flavor of the Tablet"? at Week 3

Organoleptic Questionnaire, question 5: How would you rate the strength of the flavor of the tablet? \[from 1 a rating of (Extremely bothersome) to 5 (Extremely pleasant)\]

Time frame:
End of Study (Week 3) or Early Withdrawal
Reported as:
Number · Number of participants
Number of Participants Answering the Question "How Would You Rate the Strength of the Flavor of the Tablet"? at Week 3
Number of participantsLamotrigine
Extremely bothersome2
Very bothersome14
Pleasant36
Very pleasant22
Extremely pleasant23
SecondaryNumber of Participants Answering the Question "How Would You Rate the Aftertaste of the Tablet"? at Week 3.

Organoleptic Questionnaire, question 6: How would you rate the aftertaste of the tablet (the taste remaining in your mouth after swallowing the tablet)? \[from a rating of 1 (Extremely bothersome) to 6 (Did NOT experience an aftertaste)\]

Time frame:
End of Study (Week 3) or Early Withdrawal
Reported as:
Number · Number of participants
Number of Participants Answering the Question "How Would You Rate the Aftertaste of the Tablet"? at Week 3.
Number of participantsLamotrigine
Extremely bothersome4
Very bothersome20
Pleasant25
Very pleasant7
Extremely pleasant12
I did NOT experience an aftertaste29
SecondaryNumber of Participants Answering the Question "How Satisfied Were You With the Aftertaste of the Tablet"? at Week 3

Organoleptic Questionnaire, question 7: How satisfied were you with the aftertaste of the tablet (the taste remaining in your mouth after swallowing the tablet)? \[from a rating of 1 (Extremely dissatisfied) to 6 (I did NOT experience an aftertaste)\]

Time frame:
Baseline, End of Study (Week 3) or Early Withdrawal
Reported as:
Number · Number of participants
Number of Participants Answering the Question "How Satisfied Were You With the Aftertaste of the Tablet"? at Week 3
Number of participantsLamotrigine
Extremely dissatisfied3
Very dissatisfied16
Satisfied28
Very satisfied11
Extremely satisfied11
I did NOT experience an aftertaste28
SecondaryNumber of Participants Answering the Question "Compared to Standard Tablets That Need to be Swallowed With Liquid, How Convenient or Inconvenient Did You Find This Orally Disintegrating Tablet"? at Week 3

Organoleptic Questionnaire, question 8: Compared to standard tablets that need to be swallowed with liquid, how convenient or inconvenient did you find this orally disintegrating tablet? (from a rating of 1 \[Extremely inconvenient\] to 5 \[Extremely convenient\])

Time frame:
End of Study (Week 3) or at Early Withdrawal
Reported as:
Number · Number of participants
Number of Participants Answering the Question "Compared to Standard Tablets That Need to be Swallowed With Liquid, How Convenient or Inconvenient Did You Find This Orally Disintegrating Tablet"? at Week 3
Number of participantsLamotrigine
Extremely inconvenient8
Very inconvenient9
Convenient16
Very convenient17
Extremely convenient47
SecondaryNumber of Participants Answering the Question "Compared to Standard Tablets That Need to be Swallowed With Liquid, How Easy or Difficult is it to Use This Orally Disintegrating Tablet?" at Week 3

Organoleptic Questionnaire, question 9: Compared to standard tablets that need to be swallowed with liquid, how easy or difficult is it to use this orally disintegrating tablet? \[from a rating of 1 (Extremely difficult) to 5 (Extremely easy)\]

Time frame:
End of Study (Week 3) or at Early Withdrawal
Reported as:
Number · Number of participants
Number of Participants Answering the Question "Compared to Standard Tablets That Need to be Swallowed With Liquid, How Easy or Difficult is it to Use This Orally Disintegrating Tablet?" at Week 3
Number of participantsLamotrigine
Extremely difficult2
Very difficult3
Easy17
Very easy20
Extremely easy55
SecondaryNumber of Participants Indicating a Preference for ODT or the Standard IR Tablet at Week 3

Participant indicated whether preference was for ODT or the standard IR tablet

Time frame:
End of Study (Week 3) or at Early Withdrawal
Reported as:
Number · Number of participants
Number of Participants Indicating a Preference for ODT or the Standard IR Tablet at Week 3
Number of participantsLamotrigine
Prefer ODT72
Prefer standard IR tablet25
SecondaryNumber of Companions/Caregivers Indicating Whether ODT or Standard IR Tablet is More Convenient at Week 3

Companion/Caregiver indicates whether ODT is more convenient or standard IR tablet is more convenient

Time frame:
End of Study (Week 3) or at Early Withdrawal
Reported as:
Number · Number of participants
Number of Companions/Caregivers Indicating Whether ODT or Standard IR Tablet is More Convenient at Week 3
Number of participantsLamotrigine
ODT more convenient79
Standard IR tablet more convenient18
SecondaryNumber of Participants Indicating at Week 3 (by Answering Yes/no) That They Would be More Likely to Take the ODT Formulation

Tablet Routine Questionnaire (Adherence): Adherence to the treatment was evaluated by asking if the participant would be more likely to take the ODT formulation (yes/no)

Time frame:
End of Study (Week 3) or at Early Withdrawal
Reported as:
Number · Number of participants
Number of Participants Indicating at Week 3 (by Answering Yes/no) That They Would be More Likely to Take the ODT Formulation
Number of participantsLamotrigine
Yes84
No10

Adverse events

Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lamotrigine—1/97 (1%)28/97 (28.9%)
Most frequent serious events
Most frequent serious events
EventLamotrigine
Myocardial infarctionCardiac disorders1/97
Most frequent other events
Showing 10 of 31
Most frequent other events
EventLamotrigine
HeadacheNervous system disorders5/97
AnxietyPsychiatric disorders3/97
DepressionPsychiatric disorders3/97
HypomaniaPsychiatric disorders3/97
NauseaGastrointestinal disorders2/97
Depressed moodPsychiatric disorders1/97
InsomniaPsychiatric disorders1/97
RestlessnessPsychiatric disorders1/97
Suicidal ideationPsychiatric disorders1/97
DizzinessNervous system disorders1/97

Baseline characteristics

Age, Continuous
Age, Continuous(years)Lamotrigine
Mean41.0 ± 12.07
Gender
Gender(Participants)Lamotrigine
Female83
Male14
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Lamotrigine
White94
Black2
Mixed race1
08

Study locations

18 sites
  • GSK Investigational Site
    San Diego, California 92108, United States
  • GSK Investigational Site
    Santa Ana, California 92705, United States
  • GSK Investigational Site
    Jacksonville, Florida 32257, United States
  • GSK Investigational Site
    Orange City, Florida 32763, United States
  • GSK Investigational Site
    Winter Park, Florida 32792, United States
  • GSK Investigational Site
    Marietta, Georgia 30060, United States
  • GSK Investigational Site
    Fairview Heights, Illinois 62208, United States
  • GSK Investigational Site
    Minneapolis, Minnesota 55454, United States
  • GSK Investigational Site
    St. Charles, Missouri 63301, United States
  • GSK Investigational Site
    Olean, New York 14760, United States
  • GSK Investigational Site
    Raleigh, North Carolina 27609, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45243, United States
  • GSK Investigational Site
    Cleveland, Ohio 44106, United States
  • GSK Investigational Site
    Arlington, Texas 76012, United States
  • GSK Investigational Site
    Houston, Texas 77014, United States
  • GSK Investigational Site
    Houston, Texas 77042, United States
  • GSK Investigational Site
    Norfolk, Virginia 23505, United States
  • GSK Investigational Site
    Charleston, West Virginia 25301, United States
09

References and documents

Publications

  • Sajatovic M, Thompson TR, Nanry K, Edwards S, Manjunath R. Prospective, open-label trial measuring satisfaction and convenience of two formulations of lamotrigine in subjects with mood disorders. Patient Prefer Adherence. 2013 May 7;7:411-7. doi: 10.2147/PPA.S40271. Print 2013. PubMed 23687443 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2008, a primary completion of Feb 2008 and a completion of Feb 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2009, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2007
First posted
Dec 24, 2007
Start
Jan 2008
Primary completionActual
Feb 2008
CompletionActual
Feb 2008
Results first posted
Aug 3, 2009
Last update
Dec 16, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00579982
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Dec 24, 2007
Start date
Jan 2008
Primary completion
Feb 2008
Completion
Feb 2008
Results posted
Aug 3, 2009
Last update
Dec 16, 2016

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lamotrigine

Start the discussion